Last checked at 10 Feb 2020 16:00
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
ValiRx Share News (VAL)
VAL Share
Price
VAL Share
News
VAL Share
Chat14
VAL Share
Trades19
VAL
Live RNS
VAL Share
Charts
VAL Level 2
Console
VAL Live
Share Price
VAL Broker
Ratings
VAL Directors
Deals
VAL Financial
Diary
VAL
Fundamentals
VAL Short
Positions
VAL
Media
ValiRx Information
Share Price Information for ValiRx (VAL)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.30
Bid:
3.20
Ask:
3.40
Change:
-0.15 (-4.35%)
Spread:
0.20 (6.25%)
Open:
3.45
High:
3.45
Low:
3.25
Prev. Close:
3.45
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.14 Jan 2020 14:50
ValiRx signs letter of intent in a bid to fund VAL401
(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
Read more14 Jan 2020 11:08
ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
Read more6 Jan 2020 09:59
ValiRx Raises GBP200,000 To Progress Product Development
ValiRx Raises GBP200,000 To Progress Product Development
Read more16 Dec 2019 10:17
ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
Read more28 Nov 2019 16:13
ValiRx granted US patent for 'VAL201' compound
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.
Read more28 Nov 2019 15:57
ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
Read more14 Oct 2019 13:44
ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
Read more26 Sep 2019 11:43
ValiRx Reports Narrowed Loss In First Half As Expenses Reduce
ValiRx Reports Narrowed Loss In First Half As Expenses Reduce
Read more24 Sep 2019 12:40
ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
Read more10 Sep 2019 13:45
ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints
(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and
Read more1 Aug 2019 12:01
ValiRx Granted European Patent Allowance For VAL301 Compound
(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a
Read more23 Jul 2019 16:25
Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx
(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were
Read more26 Jun 2019 14:30
US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer
(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade
Read more26 Jun 2019 10:53
ValiRx gets US patent protection for use of VAL201 peptide
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.
Read more